Xiangyang Yu

Dr. Xiangyang Yu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2024 in eClinicalMedicine
Verified
Journal Article
Open access
XYXiangyang Yu
Xiangyang Yu
CHChujian Huang
Chujian Huang
LDLongde Du
Longde Du
CWChunguang Wang
Chunguang Wang
YYYikun Yang
Yikun Yang
KMKai Ma
Kai Ma
The absolute overall survival (OS) improvement with preoperative chemotherapy or chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) patients is controversial and unsatisfactory. We designed this trial to explore the efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB NSCLC to facilitate further optimization of this therapeutic strategy. Patients diagnosed with stage IIIB NSCLC through invasive staging approaches and/or PET/CT scans and evaluated as having a high probability of radical resection of the primary lesion and metastatic lymph nodes with clear pathological margins by a multidisciplinary team were enrolled in this open-label, single-arm, phase II trial at a single centre in China. The participants received two cycles of intravenous neoadjuvant treatment with PD-1 inhibitor sintilimab (200 mg), pemetrexed (500 mg/m2) for adenocarcinoma, paclitaxel (175 mg/m2) or nab-paclitaxel (260 mg/m2) for other histological subtypes, plus carboplatin (area under the curve 5) or cisplatin (75 mg/m2) on the first day of each 3-week cycle. Surgical resection was performed 28–42 days later. After recovery from surgery, two cycles of adjuvant treatment were carried out in strict conformity with the neoadjuvant regimen, and then sintilimab maintenance monotherapy were given. The primary endpoint was major pathological response (MPR). The key secondary endpoints included the objective response rate (ORR), radical resection (R0) rate, pathological complete response (pCR) rate, event-free survival (EFS), disease-free survival (DFS), OS, treatment-related adverse events (TRAEs), surgical complications, and surgery delay rate. This trial is registered with the Chinese Clinical Trial Registry (ChiCTR2000040673). Forty-one patients were assessed for eligibility between December 2020 and August 2022; 30 patients were enrolled and given two cycles of neoadjuvant chemoimmunotherapy (neoCIT). Nineteen patients achieved a radiographic partial response, resulting in an ORR of 63.3%. Although 26 patients (86.7%) experienced TRAEs during the neoadjuvant phase, only two patients (6.7%) had ≥ grade 3 TRAEs. Surgical resection was performed on 27 patients (90%), with two patients experienced surgical delay because of coronavirus disease 2019, and the R0 rate was 96.4%. Twelve patients (44.4%) in the per-protocol (PP) population achieved an MPR, including six patients (22.2%) with a pCR. The most common postoperative complications were atrial fibrillation (6, 22.2%), pneumonitis (5, 18.5%), and heart failure (4, 14.8%); no deaths occurred within 90 days after surgery. As of October 31, 2024, the median follow-up was 34.7 months. The estimated EFS and OS rates at 36 months in the intention-to-treat population were 42.8% and 70.1%, respectively, and the estimated DFS and OS rates at 36 months in the PP population were 52.5% and 70.4%, respectively. Perioperative sintilimab plus platinum-based chemotherapy is an emerging treatment option for patients with potentially resectable stage IIIB NSCLC; it has a high response rate and tolerable treatment-related toxic effects, and enables radical resection in most patients. The Cancer Research Program of National Cancer Center (NCC201919B02), Shenzhen Clinical Research Center for Cancer (No. [2021]287), Shenzhen High-level Hospital Construction Fund, Shenzhen Key Medical Discipline Construction Fund (SZXK075) and 10.13039/501100012151 Sanming Project of Medicine in Shenzhen (SZSM201612097) funded this study.

27 November 2024 in Thoracic Cancer
Verified
Journal Article
Open access
ZYZhentao Yu
Zhentao Yu
XYXiangyang Yu
Xiangyang Yu
YXYafei Xu
Yafei Xu
YXYu Xin
Yu Xin
JHJie He
Jie He
KMKai Ma
Kai Ma
Background: Multiport robot‐assisted thoracoscopic surgery (mRATS) has been comprehensively evaluated for its clinical efficacy in numerous studies. Nevertheless, the safety and feasibility of uniportal robotic lobectomy and lymphadenectomy require further validation.Methods: The clinical data of 34 consecutive patients with lung cancer who underwent improved uniportal robotic‐assisted thoracoscopic surgery (uRATS) at our hospital between November 2023 and June 2024 were reviewed retrospectively. Camera‐centered uRATS was conducted using the da Vinci Surgical Xi system (Intuitive Surgical Inc., 1266 Kifer Road, Sunnyvale, CA 94086, USA). Descriptive statistics are expressed as numbers with percentages for categorical data or medians (ranges) or means with standard deviations for continuous data.Results: Improved uRATS lobectomy and lymphadenectomy were conducted in 34 patients with postoperative pathology‐diagnosed invasive lung cancer. Among the patients, the median number of lymph nodes dissected was 24.5 (range 10–42), and the median number of stations with lymph nodes dissected was 8 (range 6–11). The median durations of the operation and the uRATS procedure were 200 min (range, 142–330 min) and 140 min (range, 80–242 min), and the median intraoperative blood loss volume was 20 mL (range, 10–100 mL), respectively. All postoperative complications, including pneumonia (2/34, 5.8%), air leakage > 5 days (2/34, 5.8%), prolonged wound healing (1/34, 2.9%), and arrhythmia (1/34, 2.9%), were graded as Clavien–Dindo grades I–II. There were no cases of wound infection or postoperative 30‐day mortality.Conclusion: The safety and feasibility of uRATS lobectomy and lymphadenectomy using the da Vinci Surgical Xi system have been preliminarily validated.

2 January 2024 in Clinical Cancer Bulletin
Verified
Journal Article
Open access
PDF file
XYXiangyang Yu
Xiangyang Yu
FWFeng Wang
Feng Wang
KMKai Ma
Kai Ma
ZYZhentao Yu
Zhentao Yu
Nine decades ago in 1933, Evarts A. Graham performed the first successful pneumonectomy in a patient with primary pulmonary squamous cell carcinoma. The patient survived for another 30 years, which drew the curtain on the surgical treatment of lung cancer. Surgical resection continues to be the cornerstone of multidisciplinary treatment for patients with early-stage non-small cell lung cancer and a proportion of those with locally advanced disease. Moreover, recent years have seen developments in automatic control, biomechanics, robotics, image transmission, artificial intelligence, three-dimensional reconstruction and printing, biological pharmacy, and molecular biology. Therefore, there is now an increasing focus on how to integrate these technologies into lung cancer surgery to improve quality of life, resect the tumor accurately, expand the population that is suitable for surgical management, predict disease recurrence with better accuracy, and ultimately achieve long-term survival. This article systematically reviews the innovative achievements that may be detrimental to current clinical practice and in future clinical trials, and simultaneously provides a brief overview of the polyvagal perspective in this field.

19 January 2024 in Medicine
Verified
Journal Article
Open access
SLShengcheng Mm Lin
Shengcheng Mm Lin
XYXiangyang Yu
Xiangyang Yu
HYHaojie Yan
Haojie Yan
YXYafei Mm Xu
Yafei Mm Xu
KMKai Ma
Kai Ma
ZYZhentao Yu
Zhentao Yu
E2F transcription factors (E2Fs) are a family of transcription factors critical regulators of the cell cycle, apoptosis, and differentiation, thus influencing tumorigenesis. However, the specific roles of E2Fs in lung adenocarcinoma (LUAD) remain unclear. Data from The Cancer Genome Atlas (TCGA) were used. R version. 4.0.3 and multiple databases (TIMER, cBioportal, gene expression profile interaction analysis [GEPIA], LinkedOmics, and CancerSEA) were utilized to investigate mRNA expression, mutational analysis, prognosis, clinical correlations, co-expressed gene, pathway and network, and single-cell analyses. Immunohistochemistry (IHC) confirmed that E2F transcription factor 7 (E2F7) correlated with LUAD. Among the E2Fs, E2F7 was identified by constructing a prognostic model most significantly associated with overall survival (OS) in LUAD patients. The univariate and multivariate Cox regression analyses showed that E2F7, p-T stage, and p-TNM stage were closely related to OS and progression-free survival (PFS) (P < .05) in LUAD. E2F 7/8 were also identified as significantly associated with tumor stage in the GEPIA database. Compared with paracancerous tissues, E2F7 was up-regulated in LUAD by IHC, and E2F7 might be positively correlated with larger tumors and higher TNM stages. E2F7 may primarily regulate DNA repair, damage, and cell cycle processes and thus affect LUAD tumorigenesis, invasion, and metastasis by LinkedOmics and CancerSEA. E2F7 serves as a potential prognostic biomarker for LUAD.

26 April 2026 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
XYXiangyang Yu
Xiangyang Yu
JZJianfei Zhu
Jianfei Zhu
FWFeng Wang
Feng Wang
KMKai Ma
Kai Ma
XGXiaotong Guo
Xiaotong Guo
ZYZhen-Tao Yu
Zhen-Tao Yu
Background: Several clinical trials of neoadjuvant chemoimmunotherapy (neoCIT) for patients with locally advanced oesophageal carcinoma have been reported recently, with promising anti-tumour efficacy. However, systematic evaluation of the treatment patterns and clinical outcomes in a real-world cohort is lacking. Objectives: This study aimed to describe the real-world treatment patterns and short- and long-term outcomes of neoCIT in patients with resected oesophageal squamous cell carcinoma (ESCC). Design: A multicentre retrospective cohort study. Methods: Data from patients with resected ESCC who received neoCIT in routine clinical practice between January 2020 and December 2022 were retrospectively collected from three tertiary centres in China. Results: A total of 324 consecutive patients were enrolled, and the majority (82.4%) received two cycles of neoCIT. In total, 225 patients achieved a radiographic partial response (PR), resulting in an objective response rate of 69.4%. The rates of minimally invasive oesophagectomy and radical resection were 71.9% and 98.5%, respectively. Fifty-nine patients (18.2%) experienced postoperative complications, and the most common complication was anastomotic leakage (10.2%). The pathological complete response and major pathological response rates were 27.2% and 37.0%, respectively. As of August 31, 2024, the median follow-up was 24.8 months. The estimated 3-year rates of disease-free survival and overall survival were 62.3% and 71.5%, respectively. Multivariate analyses revealed that tumour grade ( p = 0.047), number of neoadjuvant therapy cycles ( p = 0.042), resection status ( p = 0.043), pathological N stage ( p < 0.001) and adjuvant treatment ( p < 0.001) were independent prognostic factors for disease-free survival. However, advanced pathological N stage was identified as the sole independent factor that correlated with worse overall survival ( p < 0.001). Conclusion: This real-world study validates the clinical efficacy and safety of neoCIT for resected oesophageal squamous cell carcinoma while demonstrating encouraging survival outcomes.

5 April 2021 in Research Square
Verified
Preprint
Open access
PDF file
XYXiangyang Yu
Xiangyang Yu
ZHZirui Huang
Zirui Huang
MZMengqi Zhang
Mengqi Zhang
YLYongbin Lin
Yongbin Lin
RZRusi Zhang
Rusi Zhang
LZLanjun Zhang
Lanjun Zhang
Background: Due to the low incidence of pulmonary large cell neuroendocrine carcinoma (LCNEC), the survival analysis for comparing lobectomy and sublobar resection (SLR) for stage IA LCNEC remains scarce. Methods: Patients diagnosed with pathological stage IA LCNEC between 1998 and 2016 were extracted from the Survenillance, Epidemiology, and End Results (SEER) database. The oncological outcomes were cancer-specific survival (CSS) and overall survival (OS). Kaplan-Meier analysis and Cox multivariate analysis were used to identify the independent prognostic factors for OS and CSS. Furthermore, propensity score matching (PSM) was performed between SLR and lobectomy to adjust the confounding factors. Results: A total of 308 patients with stage IA LCNEC met the inclusion criteria: 229 patients (74.4%) received lobectomy and 79 patients (25.6%) received SLR. Patients who underwent SLR were older (P<0.001), had smaller tumor size (P=0.010) and fewer lymph nodes dissection (P<0.001). The 5-year CSS and OS rates were 56.5% and 42.9% for SLR, and 67.8% and 55.7% for lobectomy, respectively (P=0.037 and 0.019, respectively). However, multivariate analysis did not identify any differences between SLR group and lobectomy group in CSS (P=0.135) and OS (P=0.285); and the PSM also supported these results. In addition, age at diagnosis and laterality of tumor were identified as significant predictors for CSS and OS, whereas the number of lymph nodes dissection was a significant predictor for CSS. Conclusions: Although SLR is not inferior to lobectomy in terms of oncological outcomes for patients with stage IA LCNEC, more lymph nodes can be dissected or sampled during lobectomy. Lobectomy should be considered as a standard procedure for patients with early-stage LCNEC who are able to withstand lobectomy.